Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole-Reference-Cited by-同舟云学术

Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole

Author:

Imamura Chiyo K.¹,Furihata Kenichi²³,Okamoto Shinichiro⁴,Tanigawara Yusuke¹

Affiliation:

1. Department of Clinical Pharmacokinetics and Pharmacodynamics, School of MedicineKeio UniversityTokyoJapan

2. P‐One Clinic, Keikokai Medical CorporationHachiojiTokyoJapan

3. Department of Clinical Pharmacology, School of MedicineTokai UniversityIseharaKanagawaJapan

4. Division of Hematology, Department of Internal Medicine, School of MedicineKeio UniversityTokyoJapan

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

Reference21 articles.

2. Pfizer Inc. Vfend Prescribing Information in the U.S.: voriconazole tablets injection suspension: LAB‐0311‐11.0; February2014.

3. Pfizer Inc. Vfend Prescribing Information in Japan: voriconazole tablets: Ver. 14; October2014.

5. Cytochrome P‐450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat;Sattler M;Drug Metab Dispos.,1992

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献